Patient Beliefs Regarding Benefits of Percutaneous Coronary Intervention in Chronic Stable Angina My Summer Research Project of 2014 Carla Lauture, of.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Ischemic cardiopathy. Ischemic cardiopathy is a term used to describe patients whose heart can no longer pump enough blood to the rest of their body due.
CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Can we prevent stent restenosis after coronary stent implantation
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
 What is Coronary Heart Disease?  Who is at Risk for Coronary Heart Disease?  Signs and Symptoms of Coronary Heart Disease.  How Is Coronary Heart.
Women and Heart Disease: Triage Criteria Symptoms versus Reality.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
Consent for Research Study RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic Examinations ACRIN
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Management of Stable Angina SIGN 96
Door to Balloon Times: How we got to where we are Brittany Cunningham, RN, MSN VHVI Quality Consultant July 27 th, 2011.
BHCAG Summit Minneapolis, MN February 23, 2012 Shannon Brownlee, MS Instructor, The Dartmouth Institute Acting Director, New America Foundation Health.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Symptoms Of Ischemic Heart Disease F.Nikaeen MD, Interventional Cardiologist Shariaty Hospital.
Silent Ischemia STABLE CAD
Decreasing Incidence of Cardiogenic Shock Summary and Comment by J. Stephen Bohan, MD, MS, FACP, FACEP Published in Journal Watch Emergency Medicine December.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
Cardiovascular Monitoring Coronary Artery Disease.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy David Atkins, MD, MPH Health Services Research and Development.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
By: Jasmine Parker, Ariyel Cheatham, and Qyaira Colbert.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Cardiac Rehabilitation Part I
From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.
The MASS-DAC Study.
CORONARY ARTERY DISEASE
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Cocaine-Related Chest Pain: The Year After
Ischemic Heart Disease
Successful CTO PCI Associated with Lower Mortality Risk
FATS- Familial Atherosclerosis Treatment Study
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery  Stephen.
The King of your Body - Heart
Section 5: Intervention and drug therapy
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Giuseppe Biondi Zoccai, MD
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Preventive Angioplasty in Myocardial Infarction Trial
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
American College of Cardiology Presented by Dr. Michel R. Le May
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p < for noninferiority)
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Perioperative cardiac events in endovascular repair of complex aortic aneurysms and association with preoperative studies  Guilherme L. Bub, MD, Roy K.
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Patient Beliefs Regarding Benefits of Percutaneous Coronary Intervention in Chronic Stable Angina My Summer Research Project of 2014 Carla Lauture, of Elms College Dr. Sarah Goff, of BMC

 H  Angina is pain or discomfort associated with myocardial ischemia – chest, jaw, left arm  Patients may also complain of symptoms that include indigestion, heartburn, weakness, sweating, nausea, cramping, and shortness of breath.

COURAGE - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation  2,287 participants - at least one narrow artery  Randomized to PCI vs. medical therapy for stable angina  Found that PCI reduces angina symptoms more quickly than medication but does not reduce myocardial infarction or death risk Background

 2010 – stable angina patients believe PCI will prevent MI and death (Rothberg et al.)  2014 – qualitative – cardiologists may not explicitly describe expected benefits of PCI for stable angina (Goff et al.)  2011 – letter to the editor–even if cardiologists spend time explaining PCI, patients may not completely understand – “teach back“ method is essential (Schenker & Meisel) Background

1. To assess stable angina patients’ perceptions of benefits of PCI Hypothesis: The majority of patients will believe PCI reduces risk for MI and death 2. To assess changes in informed consent process for PCI for stable angina at BMC Hypothesis: Cardiologists will report changing informed consent process following 2010 study Specific Aims

 Study design - Survey  125 Stable angina patients awaiting cardiac cath/possible stent  35 Cardiologists who refer or admit to BMC  Methods

 Questionnaire development  Modified original questionnaire  Piloted modifications with patients with stable angina awaiting PCI  Cognitive interviewing  Elicits respondent feedback on: language, comprehensibility, and relevance of questions Methods

 Conducting Survey  Approach stable angina patients awaiting cardiac cath.  Inform of purpose of the study  Read questions to patients (reduce issues with literacy)  Patient exclusions: those who speak a language other than English or Spanish or who are having procedure as pre-op for surgery or valve replacement Methods

 Cardiologists surveyed to assess what if any changes were made in consent process for stable angina patients undergoing cath/possible stent placement  Inclusions: cardiologists who admit or refer to BMC  Exclusions: none Methods

 Patients  Percent of patients who think PCI will reduce risk for MI and/or death  Why patients believe what they do about PCI benefits  Cardiologists  Reported changes in informed consent procedures since 2010 Results

 Patients: English & Spanish speaking patients only  Cardiologists: Social desirability  General: One institution Limitations

 guide/updates/medication-vs-stents-for-heart-disease- treatment  stent-warning_x.htm stent-warning_x.htm  Patients' and cardiologists' perceptions of the benefits of percutaneous coronary intervention for stable coronary disease. Schenker Y, Meisel A. Ann Intern Med Mar 1;154(5):371. doi: /  Optimal Medical Therapy with or without PCI  for Stable Coronary Disease. William E. Boden, M.D., Robert A. O’Rourke, M.D., New England Journal of Medicine. April vol. 356 no. 15 References

 Dr. Sarah Goff, Principal Investigator/Summer Scholar Mentor  Auras Atreyas, Amin Reva Kleppel, Janice Fitzgerald, Sub-investigators of “Patient Beliefs Regarding Benefits of Percutaneous Coronary Intervention in Chronic Stable Angina”  BMC &The Summer Scholars Program Thank you! Acknowledgements